---
title: "Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial"
date: 2022-06-28
enddate:
---

Published in: *Multiple Sclerosis Journal*

DOI: [10.1177/13524585221102584](https://doi.org/10.1177/13524585221102584)

<img src="https://upload.wikimedia.org/wikipedia/commons/thumb/7/77/Open_Access_logo_PLoS_transparent.svg/800px-Open_Access_logo_PLoS_transparent.svg.png" alt="drawing" width="50" align="left"/> &nbsp;&nbsp;&nbsp;This publication is available in **Open Access**! (Hybrid OA)

&nbsp;&nbsp;&nbsp;<a href="https://journals.sagepub.com/doi/pdf/10.1177/13524585221102584">Access it freely here</a>

